Kevin Outterson’s Post

𝗔𝗲𝗹𝗶𝘀 𝗙𝗮𝗿𝗺𝗮’𝘀 𝟮𝟬𝟮𝟰 𝗛𝗮𝗹𝗳-𝗬𝗲𝗮𝗿 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗶𝘁𝘀 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗮𝗻𝗱 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝘂𝘁𝗹𝗼𝗼𝗸 𝗮𝗿𝗲 𝗼𝘂𝘁 👇 As of June 30, 2024, Aelis Farma had a solid cash position of €12.6 million, not including the gross amount of €4.5 million share offering which occurred at the end of July and other non-dilutive financing currently being obtained, ensuring financial visibility until the end of 2026. During the first half of 2024, Aelis Farma made significant progress with its two clinical stage drug-candidates and an expansion of its screening capabilities. Thus, this first semester was marked by: ☑ The last patient last visit in the Phase 2B trial with AEF0117 for the treatment of cannabis use disorders (CUD) in April 2024. Although the primary endpoint was not met the preliminary results of this study show a statistically significant decrease in cannabis consumption in participants with moderate CUD. ☑ The end of recruitment for a phase 1/2 study with AEF0217 in people with Down syndrome. The results of the study will be announced in Q4 2024. ☑ The expansion of research capabilities with the transfer of the screening laboratory responsible for identifying new CB1-SSi molecules to the IECB (Institut Européen de Chimie et de Biologie) in Pessac (Bordeaux).   #AELIS #biotech #cannabisaddiction #CB1 #downsyndrome #cognitiveimpairments #neurosciences #halfyearstatement

🚨 Call for Papers – International Journal of Advanced Medical and Clinical Therapeutics 🚨 We are excited to announce that the International Journal of Advanced Medical and Clinical Therapeutics (IJAMCT) is now accepting submissions for its upcoming issue! 📝 🌟 We invite high-quality research, reviews, and case studies in the following areas: Clinical Medicine & Therapeutics 🩺 Advanced Medical Research 🧬 Pharmacology & Drug Development 💊 Evidence-Based Healthcare Practices 🌍 Medical Technology & Innovation 🚀 💡 Why publish with IJAMCT? Global Audience: Reach a worldwide network of medical professionals, researchers, and clinicians. Peer-Reviewed: Rigorous evaluation by top experts in the field. Fast Publication: Efficient and timely processing to ensure your research reaches readers quickly. Open Access: Maximizing the impact of your research with unrestricted access. 🗓️ Important Dates: Submission Deadline: 20th September 2024 Notification of Acceptance: Within 7 business days 💻 Submit your manuscript today and contribute to the advancement of medical and clinical science! Submission Link: https://lnkd.in/efU6MURD For submission guidelines and more information, visit our website: https://lnkd.in/e9mGj5EK 🔬 Let's push the boundaries of medical knowledge together! #CallForPapers #MedicalResearch #ClinicalTherapeutics #AdvancedMedicine #IJAMCT #OpenAccess #MedicalJournals #ResearchOpportunity #HealthcareInnovation

🎉 Excited to share that I have successfully completed Clinical research course ! This course has provided me with valuable insights and skills in Clinical trials,drug discovery and development, pharmacokinetics and pharmacodynamics. Looking forward to applying this knowledge in my professional journey. #Learning #ProfessionalDevelopment#Drugdiscovery

At 7 years old, Harriet Van Vleet Chair of Excellence and professor in the Department of Pharmacology, Addiction Science, and Toxicology, Alex Dopico, MD, PhD, received his first chemistry set from his parents—not knowing it would mark the beginning of a long career studying how ion channels in blood vessels and nerves function in healthy conditions and what goes wrong in disease. “As a physician, addressing health issues is a must, yet the curiosity for the unknown remains a fundamental driving force.” Learn more about Dr. Dopico's career at the story on our news site: https://lnkd.in/edAFtdKG #UTHSC #Research #HealthCare

On the new episode of Carolina Pharmacy's Unscripted, Dean Kashuba spoke with Jimmy Rosen, the CEO of Rapidly Emerging Antiviral Drug Development Initiative (READDI)! They discuss the necessity of preparing for pandemics ahead of time, the work being done in antiviral drug discovery, and about how one’s career path is not always straight-forward. Watch below:

The industry's continual pursuit of #DEI initiatives to improve clinical trials is slowly gaining the trust of patients while also proving to be cost-effective. However, the current legal landscape for DEI initiatives is unstable. This instability is trickling in to the clinical trial space. As the legal landscape continues to unfold, the question is how will it shape the future of the clinical trial space in the United States. Thank you again Christopher Escobedo Hart, Ken Getz, Pamela Tenaerts, MD, MBA, Patrick Floody, and Otis Johnson, PhD, MPA for your candor in this discussion. #clinicaltrials #diversity #equity #inclusion #patientrecruitment #healthcare #pharma #biotech #clinicalresearch

What a brilliant #WorldSmartMedicationDay webinar, including a fantastic poster and talk by Min Ci Lee from IMU University! ✨👏 Well done to all the winners and entrants! Thanks to the International Union of Basic and Clinical Pharmacology (IUPHAR) for organising and to Prof karel allegaert and Prof Sarah Hilmer for chairing! #DrugEvaluation #SafePrescribing #DrugSafety

🌟Exciting News! 🌟 We are excited to share that our recent study, co-authored by Prof. Natalie Schellack from our Department of Pharmacology at the University of Pretoria, has been published in the Elsevier International Journal of Antimicrobial Agents! 📚 The publication, titled "Antimicrobial therapeutic drug monitoring in critically ill adult patients: An international perspective on access, utilisation, and barriers," sheds light on the global challenges and disparities in antimicrobial therapeutic drug monitoring (TDM) in intensive care units. 🔍 Key findings from the study include: Delayed drug assay turnaround times as the most significant barrier to TDM utilisation, particularly in lower-income countries. Limited availability of TDM candidates and dosing software. Concerns regarding the validity of dosing software as a major barrier. This research provides valuable insights into the barriers to TDM and its impact on patient outcomes, emphasizing the need for improved access and utilisation of TDM in intensive care settings worldwide. 📖 Read the full paper here: https://lnkd.in/dSj_RKca #Pharmacology #GlobalHealth #UniversityOfPretoria #UPHealthSciences #TherapeuticDrugMonitoring #AntimicrobialResistance #IntensiveCare #GlobalHealth #ResearchCollaboration"

TGen distinguished professor Nicholas Schork, Ph.D., is pushing for a formal meeting with the FDA. He wants to discuss how to advance aggregated “n-of-1” clinical trials, which combine data from single-patient studies. Schork’s proposal involves an FDA Critical Path Innovation Meeting (CPIM). At this meeting, researchers can present emerging treatment pathways and seek guidance from FDA officials on how to use and get approval for research strategies such as aggregated patient-focused trials. Schork believes that learning to combine data from single-patient studies will accelerate drug development. This approach could lead to more personalized treatments tailored to a patient’s unique biology, behavior, and environment. Having personally worked on several n-of-1 trials, Schork says he has, “come to the realization that if we’re going to live in a precision medicine era, then we have to come up with study designs and ways of vetting drugs and health interventions that focus on individual patients’ treatment responses.” N-of-1 studies are common in rare diseases, which TGen’s Center for Rare Childhood Disorders often handles. These studies test interventions in individuals because so few people have the disorder, Schork explains. Read more at: https://bit.ly/3WIFB4O #FYP #ForYouPage #ClinicalTrial #Research #Science #FDA #Phoenix #Arizona

Today on the Aetion Evidence Hub, our very own Head of Regulatory, Nicholaas Honig, summarizes #FDA's latest #draftguidance on non-interventional studies for drug and biological products. Click the link below to learn how the Draft Guidance largely aligns with what we here at Aetion call the "show your work" concept, as reflected in the SURF, SPACE/SPIFD/SPIFD2 publications led and co-authored by Aetion scientists. https://hubs.li/Q02qk37f0